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Abstract Until now, the anatomic extent of tumor (TNM
classification) has been, by far, the most important factor to
predict the prognosis of colorectal cancer patients. However,
in recent years, data collected from large cohorts of human
cancers demonstrated that the immune contexture of the
primary tumors is an essential prognostic factor for patients'
disease-free and overall survival. Global analysis of tumor
microenvironment showed that the nature, the functional
orientation, the density, and the location of adaptive immune
cells within distinct tumor regions influence the risk of
relapse events. An immune classification of the patients was
proposed based on the density and the immune cell location
within the tumor. The immune classification has a prognostic
value that is superior to the TNM classification, and tumor
invasion is statistically dependent on the host immune
reaction. Tumor and immunological markers predicted by
systems biology methods are involved in the shaping of an
efficient immune reaction and can serve as targets for novel
therapeutic approaches. Thus, the strength of the immune
reaction could advance our understanding of cancer evolu-
tion and have important consequences in clinical practice.
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TNM staging: T is for T cells and M is for memory [1]
The outcome prediction in cancer is usually achieved by
evaluating tissue samples obtained during surgical removal
of the primary tumor, mostly focusing on their histological
characteristics. These include an atypical cell morphology,
tissue integrity, aberrant expression of markers of malignant
transformation, senescence and proliferation, various char-
acteristics of the invasive margin (IM), depth of invasion,
and the extent of vascularization. In addition, histological
or radiological analysis of both, tumor-draining and
regional lymph nodes, as well as of distant organs can be
carried out looking for evidence of metastases. Based on
these data, the evaluation of cancer progression is
performed and further serves to estimate the patient
prognosis. Available statistical data of patients with similar
progression characteristics and their actual outcome param-
eters such as average disease-free (DFS), disease-specific
(DSS), and overall survival (OS) are used for the
estimation. Until now, tumor staging (AJCC/UICC-TNM
classification) summarizes data on tumor burden (T),
presence of cancer cells in draining and regional lymph
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DOI 10.1007/s00281-011-0264-xnodes (N), and evidence for metastases (M). With the large
amount of statistical data available on cancer patients'
survival with a given progression stage, such approaches
have been shown to be valuable in estimating the outcome
in cancer [2–4].
Still, it is well known that the cancer outcome can
significantly vary between patients within the same histo-
logical tumor stage. The progression of advanced-stage
cancer can remain stable for years, and partial or full
regression of large metastatic lesions can also occur
spontaneously. For example, considering only the chest
metastatic tumors, 76 reports have demonstrated spontane-
ous regression [5]. The most common primary tumors were
renal cell carcinoma, and also hepatocellular carcinoma,
endometrial stromal sarcoma, pleomorphic liposarcoma,
and esophageal cancer. Similarly, spontaneous regression
of metastases from melanoma, and spontaneous remissions
in colorectal cancer (CRC) metastases were shown [6, 7].
On the other hand, the rapid relapse and death of early
cancer patients were reported, even after an apparently
complete surgical removal of the tumor, with undetectable
levels of residual tumor burden and without signs of
metastasis. One reason for the limited accuracy of the
traditional staging in predicting the outcome of the patients
could be the usual estimation of the tumor progression as a
largelyautonomousprocess,focusingonlyoncancercells and
without consideringtheevolutionofthe cancerasabalanceof
factors which can enhance or suppress the tumor [8].
Recently, many reports supporting the hypothesis that
cancer development is strongly influenced by the host's
immune system were published [8, 9]. This underlines the
importance of the systemic and local immunological
markers that even at the level of clinically apparent tumors
should be evaluated in predicting the outcome [8, 10].
Moreover, such markers were shown to be superior to the
AJCC/UICC-TNM staging in estimating DFS, DSS, and
OS [11–13]. In fact, the conventional histological criteria
were dependent on the intratumoral immune reaction of the
host, particularly on cytotoxic and memory T cells [1].
The infiltration of the center (CT) and of the IM of the
tumor by cytotoxic CD8+ and memory CD45RO+T cells
was shown to have a prognostic discriminatory power
superior to standard staging systems AJCC/UICC-TNM.
The quantification of those tumor-infiltrating T cells,
allowed to define a novel scoring system with strong
correlation with clinical outcome. This immune-based score
ranges from 4 (high density of CD8+ and CD45RO+Tcells
in CT and IM) to 0. Those results demonstrate several key
findings. First, patients with high immune scores have
increased disease-free and overall survival as compared
with low immune scored patients. The immune score is
superior in predicting the disease outcome as compared to
clinical parameters, including TNM staging. Second, there
is an inverse correlation between immune cell density and
tumor stage. The growth of the primary tumor and the
metastatic spread were associated with decreased intra-
tumoral immune T-cell density. The most infiltrated tumors
were in majority (60%) in situ or T1 stage tumors. In
contrast, only 18% of T4 tumors were high T cell
infiltrated. Moreover, there were no tumors in situ or T1
stage showing weak immune cell density, whereas 45% of
T4 tumors had low immune scores. Thus, it is likely that a
strong intratumoral immune response protects against
tumor progression, and a minimal tumor burden is
associated with high densities of CD8+ and GZMB+
cytotoxic T cells. Third, in patients who did not relapse,
the density of CD8-infiltrates was inversely correlated with
T stage. In contrast, in patients with recurrence, the number
of CD8+ cells was low regardless of the T stage of the
tumor. Thus, the data suggest that even in the case of a
minimal tumor invasion, patients with a low immune score
will be likely to experience a disease relapse. For these
patients, surgery may not be curative. Remarkably, the
prognostic power of the immune score was retained
regardless of whether the tumor tissue was obtained from
a CRC patient with stage I or stage IV [11, 13].
A novel classification of colorectal cancer patients based
on the immune score
In multivariate Cox analyses for DFS, DSS, and OS, we
showed that the immune parameters remained significant,
whereas the histopathological parameters did not (including
T stage and N stage) [11, 13]. Thus, based on the inverse
interrelation between the immune density and the tumor
stage, it can be hypothesized that the prognostic value of
the TNM staging could partially reflect the quality and
density of infiltrating immune cells. Whether or not
immune cells are directly implicated in the control of
tumor dissemination is not answered. However, it is
tempting to think that a weak in situ immune infiltrate
reflects a defect of the host response to the tumor challenge.
This leads to an inefficient control of early metastatic (tumor
emboli) and possibly to a defect in the generation of systemic
effectors capable of controlling the micrometastatic disease in
lymph nodes, peripheral blood, peritoneal cavity, or bone
marrow [14]. Interestingly, the long-lasting anti-tumor
capacities of memory T cells have been shown in a mouse
model of colon carcinoma metastases [15]. Those cells are
maintained in the body for long periods of time.
In the view of our results [11, 13, 16], it could be wise to
include immune markers to evaluate the prognosis of CRC
patients. Given the fact that the assessment of intratumoral
cytotoxic and memory T lymphocytes density provides an
indicator of tumor recurrence beyond the AJCC/UICC-TNM
336 Semin Immunopathol (2011) 33:335–340staging, we propose a novel classification based on the
evaluation of the host immune reaction (Im classification).
Immune scoring in early stage colorectal cancers
As stated above, in early-stage CRC patients with no
detectable lymph node or distant metastasis, surgery is the
state of the art. However, a significant number of patients
(20–25%) will recur indicating that they already had occult
metastasis at the time of surgery. There is presently no
marker to identify the group of relapsing patients that might
benefit of adjuvant therapy. We thus undertook a large
study on 602 early-stage CRC patients (stages I–II) to
assess the importance of the immune pattern from the
surgically removed tumor in predicting recurrence and
overall survival.
Based on our previous observations, we chose to classify
the patients based on the immune score (Im0 to Im4) that
quantifies the intratumoral CD45RO+and CD8+ T cells.
Forty-two percent of the patients presented a high infiltra-
tion of CD8+ and CD45RO+cells in CT and IM (Im4),
whereas 4% had a low infiltration of these cells in both
regions (Im0). Univariate analysis showed significant
differences in DFS, DSS, and OS among immune score
based patient groups. Im4 patients were at low risk, with 5-
year DFS and OS rates of 95.2% and 86.2%, respectively.
In contrast, Im0 were at high risk, with 5-year DFS and OS
rates of 25% and 27.5%, respectively. Im1 and Im2 patients
experienced a similar bad postoperative outcome. Indeed,
the cumulative DFS and OS rates of the Im1 and Im2
patients were 56.4% and 61.6%, respectively [16].
These data indicate that a stratification of the patients
based on the intratumoral CD8+ and CD45RO+cell density
could be of interest in clinical practice. In multivariate
analysis, the immune score and bowel perforation remained
the only independent prognostic factors, whereas T stage
was no longer significant. Of note, perforation represented
only 3.4% of the patients, and this proportion tends to
decrease with earlier detection of CRC in recent years. The
immune score allowed the classification of patients into
groups with distinct clinical outcome [16]. Thus, we
propose to include in clinical practice the strong and
reproducible intratumoral immune score.
Immune scoring and modulation of the immune
reaction
T helper cells
We analyzed the functional immune coordination and the
cytotoxic T cell markers in relation to T helper subpopu-
lations (Th1, Th2, Th17, and Treg) [17–19]. Figure 1
summarizes the four major groups of patients according to
immune status and outcome. Unsupervised hierarchical
clustering of a correlation matrix revealed functional
clusters of genes associated with Th17, Th2, Th1, Treg,
and cytotoxicity. Patients with high expression of the Th17
cluster had a poor prognosis, whereas patients with high
expression of the Th1 cluster had a prolonged disease-free
survival. In contrast, no prediction of the prognosis was
associated with Th2 cluster. The combined analysis of
cytotoxic and Th17 clusters gave a better discrimination for
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and low Th17 density. Altered
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Semin Immunopathol (2011) 33:335–340 337relapse. These results were confirmed by in situ analysis of
the immune density from CT and IM [18].
Patients with high density of IL17+ cells had a poor
prognosis, whereas patients with high density of CD8+
cells had a prolonged DFS. The combination of these
two markers also gave a better discrimination of patients.
In particular, patients with heterogeneous densities of
C D 8 +c e l l si nC Ta n dI Mh a v i n ga ni n t e r m e d i a t e
outcome could be discriminated in good or bad survivor
depending on the densities of the IL17+ cells [18]. As
previously reported [20] ,w ef o u n dt h a ta ni m p r o v e d
survival associated with a high density of tumor-
infiltrating FoxP3+ cells suggesting no major immuno-
suppressive role of Treg cells in CRC.
T regulatory cells and prognosis
It was reported an analysis of T cell infiltrates in large
cohorts of stage II and III CRC patients [20]. Similar to our
findings, they confirmed a low density of CD45RO+cells
in patients with early signs of metastasis. They found also
that CD45RO+and CD8+ T cells correlate with micro-
satellite instability in the tumor. High densities of intra-
tumoral CD45RO+, CD8+, and strikingly FoxP3+ cells
correlate with a good prognosis.
The question of the prognostic value of regulatory T
cells in human cancers appears indeed to be a complex
issue. Curiel et al. [21] reported that the presence of high
density of CD3+ CD4+ CD25+ FoxP3+ cells in malignant
ascites of ovarian carcinoma correlated with advanced
tumor staging and reduced survival. Those results were
confirmed in other solid tumors, such as pancreatic ductal
adenocarcinoma [22] or hepatocarcinoma [23]. Those
findings gained a large interest since they supported the
appealing hypothesis that the induction of Treg could be a
major escape mechanism for human tumors. In this light,
Treg could represent not only a prognostic marker but, even
more importantly, a target for immunotherapy.
However, in follicular lymphoma and Hodgkin's lym-
phoma [24, 25] high density of intratumoral Treg was
shown to correlate with good prognosis. FoxP3+ T cell
infiltration in head and neck cancer was associated with a
better loco-regional control of the tumor. Multivariate
analysis showed that the significant prognostic factors
related to loco-regional control were the T stage and the
intratumoral Treg infiltration [26]. In CRC, high densities
of FoxP3+ T cells were associated with microsatellite
instability [27, 28], feature usually associated with favor-
able prognosis. We found no association between the
expression of FoxP3, CTLA4, GITR, IL10, and TGFb
and the presence of lymph node or distant metastasis. In
ovarian carcinoma, the absolute number of FoxP3+
lymphocytes infiltrating the tumor epithelium was an
independent prognostic factor for longer DSS in advanced
stage and metastatic patients [29]. The issue is therefore
still open and needs more precise analysis of the relative
proportion of Treg versus helper and cytotoxic T cells, their
spatial distribution in tumor, invaded lymph nodes and
blood, of CD4 or CD8 FoxP3+ subpopulations [30], as well
as their functionality [31]. Even more, the T cell plasticity
where Treg can lose FoxP3 expression and change their
phenotype [32], and reversely, FoxP3-T cells can acquire
FoxP3, without becoming regulatory [33], adds complexity
to these analysis.
Immune scoring in other cancer types
Is the immune score specific to CRC, or it could be applied
to other cancer types as well? There have been many
reports showing that intratumoral CD8+ T cells are
independent predictors of survival or disease outcome in a
variety of malignancies, either alone or in conjunction with
additional immune markers. High density of lymphocytes,
especially T cells, has been reported of good prognosis in
melanoma, breast cancer, ovarian cancer, non-Hodgkin's
lymphoma, head and neck cancer, non-small cell lung
cancer (NSCLC), esophagus cancer, urothelial carcinoma,
endometrial cancer, malignant pleural mesothelioma [34–
40]. This supports the idea that the immune contexture,
particularly elaborated in CRC [12], could be a general
phenomenon.
One of the most studied human malignancies is CRC.
The first reports on a beneficial effect of lymphocytic
infiltration in CRC have been published 30–20 years
ago [41–44]. They were confirmed recently by studies
underlining the prominent role of memory T cells [14]a n d
CD8+ T cells [45] in predicting disease-free and overall
survival.
It is interesting to note that it does not only concern
various organs (breast, colon, lung, head and neck, kidney,
bladder, ovary, prostate…), but also various cancer cell
types (adenocarcinoma, squamous cell carcinoma, large cell
cancer, melanoma…). It concerns tumors considered as
immunogenic in which the success of active immunothera-
pies with IL2, IFN, or TIL has been documented [46], such
as melanoma or renal cell cancer as well as tumors in which
there is, so far, no success of these approaches which leaves
open the search for alternative novel immunotherapies.
This diversity in type of malignancy and stage of the
disease suggest that immune score may be a useful addition
to the evaluation of many tumor types. Whether a universal
consensus immune score can be generated is unknown;
however, there are many common features in the host
immune response against many cancer types. Considering
the probable universal character of the immune control of
338 Semin Immunopathol (2011) 33:335–340tumors, it is essential to stop ignoring it as a prognostic factor
[8] and to introduce the immune score as a marker to classify
cancers [13, 16]. This marker has a dual advantage: firstly, it
appears to be the strongest prognostic factor for disease-free
and overall survival particularly in early-stage cancers and
secondly, it provides a tool or a target for novel therapeutic
approaches. A better understanding of the interplay between
the immune contexture, the inflammatory context, the
vascularization in the microenvironment and the tumor cells
is also necessary. Where an efficient immune reaction is
generated and ultimately towards what antigens is directed
are major questions still to answer. Better understanding of
these elements and interactions should lead to the develop-
ment of novel, more efficient therapeutic strategies.
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